Wednesday, 13 Nov 2019

You are here

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

RA patients from two early RA inception cohort studies ERAS, ERAN) in the UK, Wales and Ireland were assessed for ILD and their therapies. They found 92 eligible ILD cases; 39 occurred in 1578 (2.5%) MTX exposed and 53 in 1114 (4.8%) non-MTX exposed cases.

The primary analysis showed MTX exposure was not associated with incident RA-ILD (OR 0.85, 95% CI 0.49 to 1.49, p=0.578) and there was a non-significant trend for a delayed ILD diagnosis (OR 0.54, 95% CI 0.28 to 1.06, p=0.072).

Instead, MTX exposure was associated with a significantly reduced risk of incident RA-ILD (OR 0.48, 95% CI 0.3 to 0.79, p=0.004).

Other independent risk factors included baseline (higher) age of RA onset, ever smoking, male gender, rheumatoid nodules and longer time from first RA symptom to first outpatient visit.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Frequent DMARD Discontinuations During Rheumatoid Pregnancies

A Canadian population-based study shows that pregnant women with rheumatoid arthritis (RA) frequently discontinue their DMARD medications, especially in the first trimester.

An administrative data study looked at women with RA with a singleton pregnancy who were studied for utilization of RA medications, including conventional synthetic DMARDs, biologics, glucocorticosteroids and NSAIDs.

Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

Common Physician HIPAA Violations

A nice review by Physician Sense and MDLinx discusses potential physician violations of current HIPAA law, largely driven by the digital age and common work flows. Several mistakes you you be aware of and avoid, include:

Forwarding PHI to a personal email account

FDA Issues Boxed Warning and Recommendations for Breast Implant Use

The U.S. Food and Drug Administration has issued a new draft guidance document calling for a boxed warning and delineation of risks with breast implants.

Voluntary Recall of Zantac by Sanofi/FDA

Sanofi has initiated a voluntary recall of all Zantac OTC (over-the-counter) products in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®. Zantac tablets are an oral, over-the-counter product to prevent and relieve heartburn associated with acid ingestion and sour stomach.